Vertex, Inc.(VERX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERX Vertex, Inc.

Trading 07-14 10:59:00 EDT

12.61

-0.37

-2.85%

High12.74	Low12.33	Vol294.06K
Open12.38	D1 Closing12.98	Amplitude3.20%
Mkt Cap2.04B	Tradable Cap908.88M	Total Shares162.00M
T/O3.70M	T/O Rate0.41%	Tradable Shares72.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERX","market":"US","secType":"STK","nameCN":"Vertex, Inc.","latestPrice":12.61,"timestamp":1784041132285,"preClose":12.98,"halted":0,"volume":294059,"delay":0,"changeRate":-0.028505392912172647,"floatShares":72076000,"shares":162000000,"eps":-0.040284,"marketStatus":"Trading","change":-0.37,"latestTime":"07-14 10:59:00 EDT","open":12.38,"high":12.74,"low":12.325,"amount":3702121.061598,"amplitude":0.031972,"askPrice":12.62,"askSize":102,"bidPrice":12.6,"bidSize":172,"shortable":3,"etf":0,"ttmEps":-0.040284,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784059200000},"marketStatusCode":2,"adr":0,"listingDate":1595995200000,"exchange":"NASDAQ","adjPreClose":12.98,"preHourTrading":{"tag":"盘前","latestPrice":12.41,"preClose":12.98,"latestTime":"09:05 EDT","volume":2851,"amount":35230.414263,"timestamp":1784034320409,"change":-0.57,"changeRate":-0.043914,"amplitude":0.060886},"postHourTrading":{"tag":"盘后","latestPrice":12.94,"preClose":12.98,"latestTime":"18:18 EDT","volume":1135951,"amount":14744571.6673,"timestamp":1783981117687,"change":-0.04,"changeRate":-0.003082,"amplitude":0.015408},"volumeRatio":0.77735,"impliedVol":0.861,"impliedVolPercentile":0.9841},"requestUrl":"/m/hq/s/VERX/tweets","defaultTab":"tweets","newsList":[{"id":"2651140380","title":"Vertex Minerals lifts gold sales and advances mechanised mining at Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2651140380","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651140380?lang=en_us&edition=fundamental","pubTime":"2026-07-14 07:44","pubTimestamp":1783986248,"startTime":"0","endTime":"0","summary":"The latest update is out from Vertex Minerals Ltd. ( ($AU:VTX) ). Vertex Minerals Ltd., an Australian underground gold producer, is focused on ramp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-lifts-gold-sales-and-advances-mechanised-mining-at-reward?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-lifts-gold-sales-and-advances-mechanised-mining-at-reward?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JNUG","GLTR","GUNR","PICK","CEF","BEGS","USG","GDXU","FGDL","UYM","GDXY","BAR","SGOL","AAAU","GLDM","DBC","VRTX","BTGD","DZZ","GDXD","MTX","GDX","OUNZ","DULL","VERX","PPI","DUST","GOAU","GDXJ","JDST","DGP","1OZmain","IAUM","XME","GOLY","PHYS","IAUI","SHNY","SGDM","RING","UGL","GLL","IAU","GBUG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651328144","title":"Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2651328144","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651328144?lang=en_us&edition=fundamental","pubTime":"2026-07-14 04:37","pubTimestamp":1783975020,"startTime":"0","endTime":"0","summary":"DJ Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Vertex Pharmaceuticals Inc.  slid 1.06% to $480.25 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.79% to 7,515.34 and Dow Jones Industrial Average  falling 0.26% to 52,498.64.This was the stock's fifth consecutive day of losses.Vertex Pharmaceuticals Inc. closed 10.01% short of its 52-week high of $533.67, which the company achieved on July 7th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as AbbVie Inc.  fell 0.03% to $248.00, Krystal Biotech Inc.  fell 0.65% to $363.44, and Arcturus Therapeutics Holdings Inc.  fell 3.73% to $6.71.Data source: Dow Jones Market Data, FactSet. Data compiled July 13, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERX","VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651314324","title":"Vertex Pharmaceuticals is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2651314324","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651314324?lang=en_us&edition=fundamental","pubTime":"2026-07-14 00:41","pubTimestamp":1783960860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VRTX/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 12:41 ET","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX","VERX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651120641","title":"UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2651120641","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651120641?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:55","pubTimestamp":1783950924,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $555, according to analysts polled by FactSet.Price: 483.16, Change: -2.23, Percent Change: -0.46","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERX","VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651112952","title":"BMO Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651112952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651112952?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:38","pubTimestamp":1783949888,"startTime":"0","endTime":"0","summary":"BMO Capital analyst Evan Seigerman maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $600.00. Seigerman covers the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bmo-capital-reaffirms-their-buy-rating-on-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bmo-capital-reaffirms-their-buy-rating-on-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRTX","VERX","BMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650137921","title":"Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2650137921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650137921?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:37","pubTimestamp":1783715820,"startTime":"0","endTime":"0","summary":"DJ Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Vertex Pharmaceuticals Inc.  slid 2.24% to $485.39 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.42% to 7,575.39 and the Dow Jones Industrial Average  rising 0.29% to 52,637.01.This was the stock's fourth consecutive day of losses.Vertex Pharmaceuticals Inc. closed 9.05% short of its 52-week high of $533.67, which the company achieved on July 7th.The stock demonstrated a mixed performance when compared to some of its competitors Friday, as AbbVie Inc.  fell 0.73% to $248.08, Krystal Biotech Inc.  fell 1.46% to $365.81, and Arcturus Therapeutics Holdings Inc.  fell 2.65% to $6.97.Data source: Dow Jones Market Data, FactSet. Data compiled July 10, 2026.This content was created by MarketWatch, which is operated by Dow Jone","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX","VERX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650713711","title":"Crinetics Pharmaceuticals Announces Merger Agreement With Vertex","url":"https://stock-news.laohu8.com/highlight/detail?id=2650713711","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650713711?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:34","pubTimestamp":1783715654,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals ( ($CRNX) ) has provided an announcement. On July 6, 2026, Crinetics Pharmaceuticals entered into a Merger Agreement unde...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crinetics-pharmaceuticals-announces-merger-agreement-with-vertex?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crinetics-pharmaceuticals-announces-merger-agreement-with-vertex?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999001176.SGD","IE00B19Z3B42.SGD","IE00B19Z9Z06.USD","LU1674673428.USD","BK4533","LU2362540622.SGD","LU1430594728.SGD","LU2324357040.USD","IE00B4R5TH58.HKD","LU0432979614.USD","LU2462157665.USD","LU0320765992.SGD","IE00B19Z3581.USD","LU1559883803.SGD","LU0823416689.USD","LU0234570918.USD","IE00BFTCPJ56.SGD","IBB","LU0757428866.USD","IBBQ","SG9999001176.USD","LU1093756168.USD","LU0079474960.USD","LU1093756325.SGD","LU1815336091.USD","SG9999013999.USD","BK4585","BBH","LU2456880835.USD","LU1069344957.HKD","LU0417517546.SGD","LU0289739699.SGD","PBE","VERX","LU0889565916.HKD","IE0002270589.USD","IE00B894F039.SGD","LU2362541273.HKD","BK4532","LU1585245621.USD","LU2417539215.USD","LU1674673691.USD","BIB","BK4023","BK4567","LU0256863811.USD","LU1035775433.USD","VRTX","LU0109394709.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650979653","title":"Vertex: Buy Rating Reaffirmed as Crinetics Deal Broadens Revenue Base; $575 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2650979653","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650979653?lang=en_us&edition=fundamental","pubTime":"2026-07-10 02:15","pubTimestamp":1783620922,"startTime":"0","endTime":"0","summary":"Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Vertex Pharmaceuticals, retaining the price target of $575.00. Naz Rahman has given hi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vertex-buy-rating-reaffirmed-as-crinetics-deal-broadens-revenue-base-575-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vertex-buy-rating-reaffirmed-as-crinetics-deal-broadens-revenue-base-575-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERX","VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650975689","title":"RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975689","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975689?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:11","pubTimestamp":1783613495,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $5Price: 485.78, Change: -12.65, Percent Change: -2.54","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VRTX","VERX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650916587","title":"Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2650916587","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650916587?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:36","pubTimestamp":1783542960,"startTime":"0","endTime":"0","summary":"DJ Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Vertex Pharmaceuticals Inc.  slid 4.56% to $498.43 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 0.28% to 7,482.71 and Dow Jones Industrial Average  falling 1.09% to 52,348.39.This was the stock's second consecutive day of losses.Vertex Pharmaceuticals Inc. closed 6.60% short of its 52-week high of $533.67, which the company reached on July 7th.The stock underperformed when compared to some of its competitors Wednesday, as AbbVie Inc.  fell 0.75% to $252.74, Krystal Biotech Inc.  rose 1.84% to $375.40, and Arcturus Therapeutics Holdings Inc.  fell 3.95% to $7.30.Trading volume  eclipsed its 50-day average volume of 1.5 M.Data source: Dow Jones Market Data, FactSet. Data compiled July 8, 2026.This content was created by ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX","VERX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649997379","title":"Analysts Conflicted on These Healthcare Names: Certara (CERT), Nurix Therapeutics (NRIX) and Vertex Pharmaceuticals (VRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649997379","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649997379?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:40","pubTimestamp":1783518004,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Certara (CERT), Nurix Therapeutics (NRIX) and Vertex Pharmaceutic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-certara-cert-nurix-therapeutics-nrix-and-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-certara-cert-nurix-therapeutics-nrix-and-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1035775433.USD","PBE","IE00B19Z3581.USD","LU1093756325.SGD","LU1430594728.SGD","HCSG","LU1674673428.USD","VERX","LU2237438978.USD","IDNA","LU0079474960.USD","IE00B19Z9Z06.USD","BBH","LU0128526141.USD","BK4567","BK4139","IBBQ","LU0256863811.USD","LU0432979614.USD","CERT","SG9999013999.USD","LU0058720904.USD","LU0417517546.SGD","BK4533","LU2362540622.SGD","LU0061475181.USD","BK4023","LABU","LU2362541513.USD","LU1093756168.USD","LU1585245621.USD","LU0566484027.USD","LU2362541273.HKD","LU0757428866.USD","IE00BJJMRZ35.SGD","XBI","IE0002270589.USD","IBB","IE00B19Z9P08.USD","VRTX","BIB","LU0320765992.SGD","IE0009355771.USD","IE0002141913.USD","IE00B894F039.SGD","LU1778281490.HKD","LU2417539215.USD","LU2456880835.USD","NRIX","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995637","title":"Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995637","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649995637?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:14","pubTimestamp":1783512871,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $555, according to analysts polled by FactSet.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VRTX","VERX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649956770","title":"Crinetics downgraded to In Line from Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2649956770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649956770?lang=en_us&edition=fundamental","pubTime":"2026-07-08 09:00","pubTimestamp":1783472409,"startTime":"0","endTime":"0","summary":"Evercore ISI downgraded Crinetics (CRNX) to In Line from Outperform with a price target of $85, down from $88, after Vertex Pharmaceuticals (VRTX) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crinetics-downgraded-to-in-line-from-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crinetics-downgraded-to-in-line-from-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0289739699.SGD","LU1585245621.USD","PBE","LU0061475181.USD","SG9999001176.USD","LU2236285917.USD","LU1815336091.USD","IE00B19Z9P08.USD","LU0566484027.USD","BK4007","LU1035775433.USD","LU1430594728.SGD","LU1778281490.HKD","LU0079474960.USD","LU0889565916.HKD","LU2456880835.USD","LU0823416689.USD","BK4567","VERX","IDNA","IE0009355771.USD","BK4533","CRNX","IE00BFTCPJ56.SGD","IE00BZ9MQY76.HKD","IE00B19Z9Z06.USD","BIB","LU0109394709.USD","IBB","IBBQ","IE00B2B36J28.USD","LU0234570918.USD","LU2324357040.USD","LU2462157665.USD","SG9999013999.USD","LU1093756325.SGD","LU2362541273.HKD","BK4139","BBH","BK4023","LU1559883803.SGD","SGXZ57979304.SGD","VRTX","IE0002270589.USD","LU1674673691.USD","LU0417517546.SGD","SG9999001176.SGD","LU1069344957.HKD","BK4588","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649403956","title":"Vertex (VERX) Could Be 28% Undervalued As TD Cowen Backs Its Profit Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2649403956","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649403956?lang=en_us&edition=fundamental","pubTime":"2026-07-08 08:37","pubTimestamp":1783471024,"startTime":"0","endTime":"0","summary":"Vertex (VERX) drew fresh investor attention after TD Cowen initiated coverage, alongside the company’s recent first quarter beat, the Brinta e-invoicing acquisition and a new Value Creation Plan focused on profitability and free cash flow.\nSee our latest analysis for Vertex.\nVertex’s recent 1-day share price return of 4.28% and 7-day share price return of 16.72% suggest short term momentum is building. However, the year-to-date share price return of 29.51% and 1-year total shareholder return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-verx/vertex/news/vertex-verx-could-be-28-undervalued-as-td-cowen-backs-its-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-verx/vertex/news/vertex-verx-could-be-28-undervalued-as-td-cowen-backs-its-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2362541273.HKD","LU2417539215.USD","LU1815336091.USD","SG9999001176.SGD","IE00B894F039.SGD","BK4566","LU0757428866.USD","IE0002270589.USD","LU2462157665.USD","TD","IE00BJT1NW94.SGD","LU1674673428.USD","IE00BFTCPJ56.SGD","IBBQ","IDNA","SG9999013999.USD","COWN","LU1093756168.USD","IE00BZ9MQY76.HKD","LU2237438978.USD","BBH","BK4139","LU1093756325.SGD","LU1430594728.SGD","BIB","GSIB","IE00B4R5TH58.HKD","LU2324357040.USD","LU0079474960.USD","LU0058720904.USD","IE00B19Z9Z06.USD","IE0002141913.USD","IE00B19Z3581.USD","LU0289739699.SGD","SG9999001176.USD","LU1778281490.HKD","LU0061475181.USD","PBE","VERX","LU1069344957.HKD","LU1674673691.USD","LU2236285917.USD","SGXZ57979304.SGD","VRTX","LU0109394709.USD","IE0009355771.USD","LU2456880835.USD","IBB","BK4567","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649958849","title":"Press Release: Vertex to Announce Second Quarter 2026 Financial Results on August 3rd","url":"https://stock-news.laohu8.com/highlight/detail?id=2649958849","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649958849?lang=en_us&edition=fundamental","pubTime":"2026-07-08 05:04","pubTimestamp":1783458240,"startTime":"0","endTime":"0","summary":"BOSTON--(BUSINESS WIRE)--July 07, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","LU0566484027.USD","LU0757428866.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","BK4532","IE00B4R5TH58.HKD","LU2362541513.USD","BBH","IE0002141913.USD","IE00B19Z3581.USD","LU0256863811.USD","SG9999001176.USD","PBE","BIB","LU0234570918.USD","BK4567","LU2417539215.USD","LU0432979614.USD","SGXZ57979304.SGD","LU0823416689.USD","IE00B19Z3B42.SGD","IE00BFTCPJ56.SGD","LU1815336091.USD","VRTX","BK4139","IBB","BK4533","LU1093756325.SGD","LU1069344957.HKD","LU0417517546.SGD","SG9999001176.SGD","LU1778281490.HKD","LU2236285917.USD","LU2456880835.USD","LU0058720904.USD","LU2462157665.USD","LU2237438978.USD","BK4023","LU1674673428.USD","IDNA","LU0079474960.USD","LU1674673691.USD","IE00BJJMRZ35.SGD","LU2362540622.SGD","LU0061475181.USD","IE00B2B36J28.USD","LU1430594728.SGD","IBBQ","VERX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649934336","title":"Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2649934336","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649934336?lang=en_us&edition=fundamental","pubTime":"2026-07-08 01:36","pubTimestamp":1783445763,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals'  planned $10 billion acquisition of Crinetics Pharmaceuticals  may prompt investor questions on the timing of the deal with several major clinical trial results already expected in early 2027, UBS Securities said Monday in a note.UBS said the deal adds two important rare-disease drugs: Palsonify, used to treat acromegaly, a condition caused by excess growth hormone, and atumelnant, now in late-stage testing for congenital adrenal hyperplasia, a disorder that affects hormone production.Vertex on Monday described the acquisition as a potential blockbuster with expected sales of more than $5 billion.The near-term focus will stay on rival cystic fibrosis data expected this summer, while Vertex's own 2027 trial results should provide additional catalysts, UBS said.UBS has a buy rating on Vertex stock with a $545 price target.Vertex shares fell 1% in Tuesday trading, and Crinetics declined 0.5%.Price: 524.45, Change: -5.14, Percent Change: -0.97","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237438978.USD","LU2362540622.SGD","IE00B19Z9P08.USD","LU0823416689.USD","IE00B4R5TH58.HKD","IE0002270589.USD","IE0009355771.USD","LU1093756325.SGD","BK4588","LU0320765992.SGD","LU1674673428.USD","BIB","LU1430594728.SGD","LU0234570918.USD","BK4585","LU2324357040.USD","SG9999001176.SGD","BK4139","CRNX","BK4007","LU1778281490.HKD","BK4532","IE00B19Z9Z06.USD","IE00BZ9MQY76.HKD","IBBQ","LU0109394709.USD","LU0079474960.USD","LU2417539215.USD","LU0566484027.USD","LU1585245621.USD","LU2462157665.USD","IDNA","LU0417517546.SGD","VERX","LU0061475181.USD","IE00B19Z3581.USD","LU0289739699.SGD","IBB","LU0432979614.USD","SG9999013999.USD","VRTX","LU0889565916.HKD","IE00B894F039.SGD","LU0058720904.USD","LU0757428866.USD","PBE","SG9999001176.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649931580","title":"Crinetics downgraded to Market Perform from Outperform at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2649931580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649931580?lang=en_us&edition=fundamental","pubTime":"2026-07-08 00:40","pubTimestamp":1783442416,"startTime":"0","endTime":"0","summary":"Citizens analyst Jonathan Wolleben downgraded Crinetics (CRNX) to Market Perform from Outperform after Vertex Pharmaceuticals (VRTX) agreed to acqu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crinetics-downgraded-to-market-perform-from-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crinetics-downgraded-to-market-perform-from-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0432979614.USD","LU2462157665.USD","BK4588","IE0002270589.USD","BK4023","IE00B19Z9P08.USD","IE0002141913.USD","LU1674673428.USD","LU0234570918.USD","BBH","LU2362541513.USD","LU2324357040.USD","BK4007","LU0320765992.SGD","IE0009355771.USD","LU2237438978.USD","IE00B4R5TH58.HKD","IBB","LU1815336091.USD","PBE","LU0823416689.USD","IE00BJJMRZ35.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","LU0757428866.USD","BK4139","LU0061475181.USD","BK4532","IE00BZ9MQY76.HKD","LU0109394709.USD","SG9999001176.SGD","LU1430594728.SGD","LU1778281490.HKD","IDNA","IE00BJT1NW94.SGD","LU0256863811.USD","IE00B19Z9Z06.USD","LU1093756325.SGD","BK4567","LU0889565916.HKD","VERX","VRTX","BIB","CRNX","LU1585245621.USD","LU0079474960.USD","SG9999001176.USD","IE00B894F039.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649933216","title":"Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2649933216","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649933216?lang=en_us&edition=fundamental","pubTime":"2026-07-07 22:00","pubTimestamp":1783432820,"startTime":"0","endTime":"0","summary":"Wedbush notes that Vertex Pharmaceuticals (VRTX) agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85/share in cash. Crinetics now trades ess...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wedbush-sees-biocryst-ascendis-as-potential-next-targets-after-crinetics-deal-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wedbush-sees-biocryst-ascendis-as-potential-next-targets-after-crinetics-deal-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2462157665.USD","BK4588","IE0002270589.USD","LU2236285917.USD","BK4023","IE0002141913.USD","LU2456880835.USD","LU0234570918.USD","IE00B19Z3B42.SGD","BBH","LU2324357040.USD","BK4007","LU0320765992.SGD","LU2237438978.USD","IBB","LU1815336091.USD","PBE","LU0823416689.USD","BK4533","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0417517546.SGD","BK4139","LU1093756168.USD","LU0061475181.USD","IE00BZ9MQY76.HKD","LU1674673691.USD","LU2362540622.SGD","IE00B19Z3581.USD","LU1430594728.SGD","LU1778281490.HKD","IDNA","LU1093756325.SGD","IE00B19Z9Z06.USD","BK4567","LU2362541273.HKD","SG9999013999.USD","SGXZ57979304.SGD","VERX","IE00B2B36J28.USD","VRTX","BIB","LU2417539215.USD","CRNX","LU1585245621.USD","LU1069344957.HKD","LU0079474960.USD","LU1559883803.SGD","IE00B894F039.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649903938","title":"Cantor Sees 'clear Strategic Rationale' Behind Vertex's Buy of Crinetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2649903938","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649903938?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:19","pubTimestamp":1783430340,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals' roughly $10 billion purchase of Crinetics Pharmaceuticals provides another near-term launch narrative with Palsonify, a treatment for acromegaly, Cantor analysts say in a research note. It also offers a clinically compelling program with multi-blockbuster potential in atumelnant, a possible treatment for congenital adrenal hyperplasia and Cushing's Syndrome, the analysts add. \"Together, these assets give Vertex a foothold in endocrinology--a fifth therapeutic area for the company,\" they write. \"We see clear strategic rationale: addition of solid, innovative science, with atumelnant carrying relatively modest binary risk.\" Vertex shares are roughly flat in premarket trading Tuesday, while Crinetics shares double.  Dow Jones NewswiresJuly 07, 2026 09:19 ET Copyright  2026 Dow Jones & Company, Inc.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","VRTX","LU2362541273.HKD","IE00B19Z9Z06.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IDNA","LU1430594728.SGD","LU0566484027.USD","IE00BZ9MQY76.HKD","BBH","LU1674673691.USD","IBBQ","LU0256863811.USD","LU0757428866.USD","LU0109394709.USD","LU0234570918.USD","IBB","BK4007","LU0079474960.USD","LU2236285917.USD","BIB","VERX","BK4567","LU0432979614.USD","IE00B894F039.SGD","BK4139","LU1674673428.USD","LU2237438978.USD","LU0320765992.SGD","LU1815336091.USD","LU1093756168.USD","LU2417539215.USD","BK4532","CRNX","IE00B19Z3B42.SGD","SG9999013999.USD","SGXZ57979304.SGD","LU1778281490.HKD","LU0289739699.SGD","BK4585","IE00B19Z3581.USD","IE00BJT1NW94.SGD","LU2324357040.USD","LU0058720904.USD","LU1585245621.USD","LU2456880835.USD","PBE","LU0061475181.USD","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649498051","title":"Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2649498051","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649498051?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:24","pubTimestamp":1783427040,"startTime":"0","endTime":"0","summary":"Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to its rare disease portfolio.","market":"sh","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=260,format=auto,quality=85/files/images/story/2026/07/07/Vertex-Pharmaceuticals-Incorporated--All.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=260,format=auto,quality=85/files/images/story/2026/07/07/Vertex-Pharmaceuticals-Incorporated--All.jpg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/m-a/26/07/60302092/vertex-sees-over-5-billion-peak-sales-potential-from-crinetics-assets","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/m-a/26/07/60302092/vertex-sees-over-5-billion-peak-sales-potential-from-crinetics-assets","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["SKIS","VERX","VRTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vertexinc.com","stockEarnings":[{"period":"1week","weight":0.0101},{"period":"1month","weight":0.057},{"period":"3month","weight":0.1336},{"period":"6month","weight":-0.3344},{"period":"1year","weight":-0.6235},{"period":"ytd","weight":-0.35}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0788},{"period":"6month","weight":0.0852},{"period":"1year","weight":0.2013},{"period":"ytd","weight":0.0986}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vertex, Inc. provides tax technology solutions for retail, communication, leasing, retail trade, wholesale trade, technology, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, analytics and insights, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.050134},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.037654},{"month":3,"riseRate":0.5,"avgChangeRate":-0.000804},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.00731},{"month":5,"riseRate":0.5,"avgChangeRate":-0.002629},{"month":6,"riseRate":0.5,"avgChangeRate":-0.017106},{"month":7,"riseRate":0.5,"avgChangeRate":0.014708},{"month":8,"riseRate":0.666667,"avgChangeRate":0.038495},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.031162},{"month":10,"riseRate":0.833333,"avgChangeRate":0.084182},{"month":11,"riseRate":0.5,"avgChangeRate":0.032922},{"month":12,"riseRate":0.333333,"avgChangeRate":0.008707}],"exchange":"NASDAQ","name":"Vertex, Inc.","nameEN":"Vertex, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vertex, Inc.(VERX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vertex, Inc.(VERX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vertex, Inc.,VERX,Vertex, Inc.股票,Vertex, Inc.股票老虎,Vertex, Inc.股票老虎国际,Vertex, Inc.行情,Vertex, Inc.股票行情,Vertex, Inc.股价,Vertex, Inc.股市,Vertex, Inc.股票价格,Vertex, Inc.股票交易,Vertex, Inc.股票购买,Vertex, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vertex, Inc.(VERX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vertex, Inc.(VERX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}